Imunon (NASDAQ:IMNN) specializes in pioneering the development of novel immunotherapies aimed at treating a variety of cancers. With a focus on leveraging cutting-edge scientific research, Imunon strives to unlock new pathways in immune modulation to combat malignancies. The company's robust project pipeline is centered on advancing treatments that harness the body's own immune system to fight cancer more effectively. Imunon is firmly committed to its mission of bringing groundbreaking cancer therapies from the lab to the clinic, thereby aiming to improve patient outcomes and enhance quality of life for those battling cancer.